Inceptua receives approval of marketing authorization transfer of Apealea® (paclitaxel micellar) for the treatment of ovarian cancer Kumar Jeetendra | December 14, 2021 LUXEMBOURG – 14 December 2021 – Life Science Newswire – Inceptua Group – pharmaceutical company and service partner – today announces that the European Commission (EC) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the transfer of the marketing authorization for Apealea® (paclitaxel micellar) from Oasmia Pharmaceutical AB to Inceptua AB. …
HiMedia Laboratories Announces Receipt of CE-IVD Certifications to their COVID-19 Detection Portfolio Kumar Jeetendra | December 15, 2021 HiMedia Laboratories – HiGenoMB® is proud to announce that we have received CE-IVD certifications for the new additions to our COVID-19 Detection Portfolio. “Receiving CE-IVD certifications for the triplex RT PCR kit and Dry-swab method kit are two more additions in our COVID-Diagnostics product range. CE-IVD certifications are a mark of highly innovative but regulatory …
Hyris fully embraces the Immunology sector to better fight COVID-19 and beyond, presenting its new, disruptive T-Cell test to the international conference “A-Wish” Kumar Jeetendra | December 16, 2021 London, UK – 15th December 2021 – Life Science Newswire – As the COVID-19 pandemic keeps causing concerns, with new variants spreading worldwide, it is now widely recognized that we must move beyond a “test&trace” only approach. World leaders and health institutions today aim to achieve high immunity rates among the population, facing the unprecedented …
Cipla acquires stake in Clean Max Auriga Power LLP; progresses towards championing its ESG agenda Kumar Jeetendra | December 16, 2021 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has acquired up to 33% of partnership interest in Clean Max Auriga Power LLP (Limited Liability Partnership). This agreement is in line with the Company’s commitment to enhance the share of renewable power source in its operation and …
Eppendorf Research plus is the first pipette to receive My Green Lab ACT label Kumar Jeetendra | December 18, 2021 The Eppendorf Research® plus single-channel pipette line-up with variable volume has been certified with an “ACT®” Environmental Impact Factor Label by the “My Green Lab®” non-profit organization. By emphasizing Accountability, Consistency, and Transparency (ACT) around manufacturing, energy and water use, packaging, and end-of-life, the ACT label makes it easier for labs to choose more sustainable …
Cipla Receives Final Approval for Lanreotide Injection Kumar Jeetendra | December 19, 2021 Mumbai, India, & New Jersey, USA: December 19, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”)and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”), today announced that it has received final approval for its Lanreotide Injection, from the United States Food and Drug Administration (US FDA). The …
Stewardship, biomarkers, and advanced diagnostics to manage sepsis and antimicrobial resistance Kumar Jeetendra | December 20, 2021 Antimicrobial resistance (AMR) is a growing global problem and because the management of COVID-19 is increasingly becoming dependent on pharmacological interventions, there is greater risk for accelerating the evolution and spread of antimicrobial resistance. According to the WHO, AMR is the largest global health threat in the 21st century that requires urgent measures. Common infections …
Moisture Sorption of EC Standard Reference Material RM 302 on a DVS Instrument Kumar Jeetendra | December 23, 2021 Microcrystalline cellulose (RM 302) is a standard EC reference material for validation of the measurement of water sorption isotherms of food materials following the COST 90 procedure [1]. This procedure involves the periodic weighing of samples stored over saturated salt solutions until equilibrium is established (nominally after 7 days). The moisture content RM 302 at …
Thermo Scientific CO2 Resistant Shaker: provide greater reliability, flexibility and ease of use for varied cell culture applications, compared to a dedicated incubated CO₂ shaker Kumar Jeetendra | December 23, 2021 Flexibility and reliability are the keys to good laboratory equipment and a CO₂ resistant shaker is designed for both. Flexibility allows it to go from the CO₂ incubator to the benchtop to the microbiological incubator, for culturing mammalian suspension cells or insect cells or bacteria and yeast. Reliability comes from sealed electronics, minimal heat production, …
Delmicron: All you need to know about new COVID-19 variant Kumar Jeetendra | December 24, 2021 The escalating incidences of omicron variants across European countries has raised questions regarding possible a new wave of COVID-19 throughout the world. While scientists are still trying to figure out the nature of this variant in order in order to determine the best prevention strategy, a different variant is gaining attention. It is called Delmicron …
New drug Molnupiravir can be the solution for our fight against COVID-19 Kumar Jeetendra | December 28, 2021 Mumbai, 28th December 2021: As countries prepare themselves to fight a possible ‘next wave’. The new variant – Omicron has been making headline and a surge in covid 19 cases are evident. According to a study based on population-level evidence, the recently identified Omicron variant of SARS-CoV-2 is associated with a substantial ability to evade …
Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu® (Molnupiravir 200 mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and who have high risk of progression of the disease including hospitalization or death. Kumar Jeetendra | December 28, 2021 Mumbai, India; December 28, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has been granted Emergency Use Authorisation(EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country. Cipla plans to launch Molnupiravir under the brand name Cipmolnu®. …
